People · Operator
Named in public records as an officer, director or promoter · active 2010–2010 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Columbia Laboratories Inc | — | Pharmaceuticals | Series B | $24.5M | $834.1M | 2010 |
James S. Crofton at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James S. Crofton on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Selwyn P. Oskowitz, M.D. | 1 | 1 |
| Michael A. McGrane | 1 | 1 |
| Stephen G. Kasnet | 1 | 1 |
| Anthony R. Campbell | 1 | 1 |
| Lawrence A. Gyenes | 1 | 1 |
| Valerie L. Andrews | 1 | 1 |
| Frank C. Condella | 1 | 1 |
| Edward A. Blechschmidt | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.